Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypersensitivity Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Not applicable Interventional

Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis

NCT00609687
View directory record Official record
Conditions
Sarcoidosis-associated Ocular Inflammation
Interventions
Diagnostic Vitrectomy
Procedure
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

NCT04065555
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

NCT00832585
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Alefacept
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 1 Interventional

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

NCT01056159
View directory record Official record
Conditions
Asthma
Interventions
Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jun 9, 2026, 11:36 PM EDT
Completed No phase listed Observational

Assessment of Influence of Vitamin D on Insulin Secretion and Sensitivity in Obese Teenage Girls

NCT00851396
View directory record Official record
Conditions
Vitamin D Deficiency, Insulin Resistance, Insulin Sensitivity, Obesity
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Jun 9, 2026, 11:36 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies

NCT04162795
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Loratadine (Claritin, BAY76-2211)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jun 9, 2026, 11:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Tape Harvesting Study

NCT02125695
View directory record Official record
Conditions
Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
Interventions
Skin Taping, Blood Sampling, Skin Biopsy
Procedure
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

NCT02643862
View directory record Official record
Conditions
Food Allergy
Interventions
Xolair, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 9, 2026, 11:36 PM EDT
Withdrawn No phase listed Observational

Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients

NCT05661422
View directory record Official record
Conditions
Pediatric Respiratory Diseases, Asthma, RSV Infection, COVID-19
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jun 9, 2026, 11:36 PM EDT
Completed No phase listed Observational

Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors

NCT01029665
View directory record Official record
Conditions
Hernia, Diaphragmatic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
4 Years to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jun 9, 2026, 11:36 PM EDT
Terminated No phase listed Observational

Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma

NCT00837395
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

NCT01641081
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jun 9, 2026, 11:36 PM EDT
Terminated Phase 3 Interventional Results available

Ramelteon for Insomnia Comorbid With Asthma

NCT00869167
View directory record Official record
Conditions
Insomnia, Asthma
Interventions
Ramelteon
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BREATHE-Peds Pilot- II III Trial and Post Trial

NCT05832437
View directory record Official record
Conditions
Asthma in Children
Interventions
BREATHE-Peds Intervention, Control Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 14 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 9, 2026, 11:36 PM EDT
Completed Not applicable Interventional

Technology- Assisted Stepped Care Intervention Study

NCT03733457
View directory record Official record
Conditions
Asthma
Interventions
Technology-assisted Stepped-care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jun 9, 2026, 11:36 PM EDT
Recruiting Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
85
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 9, 2026, 11:36 PM EDT
Completed No phase listed Observational

Outcomes From an Asthma Disease Management Program

NCT00137722
View directory record Official record
Conditions
Asthma
Interventions
Education of providers and their staff, Case management, Payment for desired behaviors
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Jun 9, 2026, 11:36 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

NCT03883412
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Exercise, Liraglutide
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jun 9, 2026, 11:36 PM EDT
Recruiting Phase 1 Interventional

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

NCT05942300
View directory record Official record
Conditions
Recurrent Ovarian Cancer
Interventions
CPI-0209, carboplatin
Drug
Lead sponsor
Lan Coffman
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jun 9, 2026, 11:36 PM EDT
Recruiting Phase 2 Interventional

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
54
States / cities
Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 9, 2026, 11:36 PM EDT